1alpha,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport - PubMed (original) (raw)
. 2005 Dec;289(6):G1036-42.
doi: 10.1152/ajpgi.00243.2005. Epub 2005 Jul 14.
Affiliations
- PMID: 16020653
- DOI: 10.1152/ajpgi.00243.2005
Free article
1alpha,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport
Olga I Kolek et al. Am J Physiol Gastrointest Liver Physiol. 2005 Dec.
Free article
Abstract
Fibroblast growth factor (FGF)23 is a phosphaturic hormone that decreases circulating 1alpha,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] and elicits hypophosphatemia, both of which contribute to rickets/osteomalacia. It has been shown recently that serum FGF23 increases after treatment with renal 1,25(OH)(2)D(3) hormone, suggesting that 1,25(OH)(2)D(3) negatively feedback controls its levels by inducing FGF23. To establish the tissue of origin and the molecular mechanism by which 1,25(OH)(2)D(3) increases circulating FGF23, we administered 1,25(OH)(2)D(3) to C57BL/6 mice. Within 24 h, these mice displayed a dramatic elevation in serum immunoreactive FGF23, and the expression of FGF23 mRNA in bone was significantly upregulated by 1,25(OH)(2)D(3), but there was no effect in several other tissues. Furthermore, we treated rat UMR-106 osteoblast-like cells with 1,25(OH)(2)D(3), and real-time PCR analysis revealed a dose- and time-dependent stimulation of FGF23 mRNA concentrations. The maximum increase in FGF23 mRNA was 1,024-fold at 10(-7) M 1,25(OH)(2)D(3) after 24-h treatment, but statistically significant differences were observed as early as 4 h after 1,25(OH)(2)D(3) treatment. In addition, using cotreatment with actinomycin D or cycloheximide, we observed that 1,25(OH)(2)D(3) regulation of FGF23 gene expression occurs at the transcriptional level, likely via the nuclear vitamin D receptor, and is dependent on synthesis of an intermediary transfactor. These results indicate that bone is a major site of FGF23 expression and source of circulating FGF23 after 1,25(OH)(2)D(3) administration or physiological upregulation. Our data also establish FGF23 induction by 1,25(OH)(2)D(3) in osteoblasts as a feedback loop between these two hormones that completes a kidney-intestine-bone axis that mediates phosphate homeostasis.
Similar articles
- Autocrine/paracrine action of vitamin D on FGF23 expression in cultured rat osteoblasts.
Tang WJ, Wang LF, Xu XY, Zhou Y, Jin WF, Wang HF, Gao J. Tang WJ, et al. Calcif Tissue Int. 2010 May;86(5):404-10. doi: 10.1007/s00223-010-9355-2. Epub 2010 Mar 31. Calcif Tissue Int. 2010. PMID: 20354682 - Fibroblast growth factor 23 production in bone is directly regulated by 1{alpha},25-dihydroxyvitamin D, but not PTH.
Saji F, Shigematsu T, Sakaguchi T, Ohya M, Orita H, Maeda Y, Ooura M, Mima T, Negi S. Saji F, et al. Am J Physiol Renal Physiol. 2010 Nov;299(5):F1212-7. doi: 10.1152/ajprenal.00169.2010. Epub 2010 Aug 25. Am J Physiol Renal Physiol. 2010. PMID: 20739393 - Vitamin D receptor: key roles in bone mineral pathophysiology, molecular mechanism of action, and novel nutritional ligands.
Jurutka PW, Bartik L, Whitfield GK, Mathern DR, Barthel TK, Gurevich M, Hsieh JC, Kaczmarska M, Haussler CA, Haussler MR. Jurutka PW, et al. J Bone Miner Res. 2007 Dec;22 Suppl 2:V2-10. doi: 10.1359/jbmr.07s216. J Bone Miner Res. 2007. PMID: 18290715 - Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease.
Stubbs J, Liu S, Quarles LD. Stubbs J, et al. Semin Dial. 2007 Jul-Aug;20(4):302-8. doi: 10.1111/j.1525-139X.2007.00308.x. Semin Dial. 2007. PMID: 17635819 Review. - The role of bone in phosphate metabolism.
Fukumoto S. Fukumoto S. Mol Cell Endocrinol. 2009 Oct 30;310(1-2):63-70. doi: 10.1016/j.mce.2008.08.031. Epub 2008 Sep 6. Mol Cell Endocrinol. 2009. PMID: 18822343 Review.
Cited by
- Absence of claudin-3 does not alter intestinal absorption of phosphate in mice.
Radványi Z, Schnitzbauer U, Pastor-Arroyo EM, Hölker S, Himmerkus N, Bleich M, Müller D, Breiderhoff T, Hernando N, Wagner CA. Radványi Z, et al. Pflugers Arch. 2024 Oct;476(10):1597-1612. doi: 10.1007/s00424-024-02998-x. Epub 2024 Aug 8. Pflugers Arch. 2024. PMID: 39115555 Free PMC article. - Vitamin D3 suppresses Npt2c abundance and differentially modulates phosphate and calcium homeostasis in Npt2a knockout mice.
Thomas L, Dissanayake LV, Tahmasbi M, Staruschenko A, Al-Masri S, Dominguez Rieg JA, Rieg T. Thomas L, et al. Sci Rep. 2024 Jul 23;14(1):16997. doi: 10.1038/s41598-024-67839-4. Sci Rep. 2024. PMID: 39043847 Free PMC article. - Vitamin D and Cardiovascular Diseases: From Physiology to Pathophysiology and Outcomes.
Nardin M, Verdoia M, Nardin S, Cao D, Chiarito M, Kedhi E, Galasso G, Condorelli G, De Luca G. Nardin M, et al. Biomedicines. 2024 Mar 30;12(4):768. doi: 10.3390/biomedicines12040768. Biomedicines. 2024. PMID: 38672124 Free PMC article. Review. - Emerging concepts on the FGF23 regulation and activity.
Rivoira MA, Peralta López ME, Areco V, Díaz de Barboza G, Dionisi MP, Tolosa de Talamoni N. Rivoira MA, et al. Mol Cell Biochem. 2024 Apr 6. doi: 10.1007/s11010-024-04982-6. Online ahead of print. Mol Cell Biochem. 2024. PMID: 38581553 Review. - Gα11 deficiency increases fibroblast growth factor 23 levels in a mouse model of familial hypocalciuric hypercalcemia.
Ay B, Cyr SM, Klovdahl K, Zhou W, Tognoni CM, Iwasaki Y, Rhee EP, Dedeoglu A, Simic P, Bastepe M. Ay B, et al. JCI Insight. 2024 Mar 26;9(9):e178993. doi: 10.1172/jci.insight.178993. JCI Insight. 2024. PMID: 38530370 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources